Generic Zometa® Launches
Generic Zometa® Launches – On March 5, 2013, Sagent Pharmaceuticals received final FDA approval and launched the generic equivalent of Zometa® (zoledronic acid). Novartis’ branded product had annual U.S. sales of approximately $1.2B.
Zometa® is indicated for the treatment of high blood calcium levels (hypercalcemia) that sometimes occur in patients with cancer, as well as the treatment of bone damage caused by Paget’s disease, multiple myeloma, and cancers that spread to the bone.
